about
Prevalence and antibiogram of Extended Spectrum β-Lactamase (ESBL) producing Gram negative bacilli and further molecular characterization of ESBL producing Escherichia coli and Klebsiella sppCurrent concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosaEmergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological studyOptimizing antimicrobial therapy in critically ill patientsEscherichia coli in Europe: an overviewOverview of ESBL-producing Enterobacteriaceae from a Nordic perspectiveResistance mechanismsTemocillin revivedThe sudden dominance of blaCTX-M harbouring plasmids in Shigella spp. Circulating in Southern VietnamOrigins and evolution of antibiotic resistanceExcess positional mutual information predicts both local and allosteric mutations affecting beta lactamase drug resistance.Emergence of human pandemic O25:H4-ST131 CTX-M-15 extended-spectrum-beta-lactamase-producing Escherichia coli among companion animals.CTX-M Enzymes: Origin and Diffusion.Why the extended-spectrum beta-lactamases SHV-2 and SHV-5 are "hypersusceptible" to mechanism-based inhibitorsA qPCR and multiplex pyrosequencing assay combined with automated data processing for rapid and unambiguous detection of ESBL-producers Enterobacteriaceae.Multi-locus variable number of tandem repeat analysis for rapid and accurate typing of virulent multidrug resistant Escherichia coli clonesThe impact of different antibiotic regimens on the emergence of antimicrobial-resistant bacteriaDissemination of Escherichia coli with CTX-M type ESBL between humans and yellow-legged gulls in the south of France.Pharmacodynamics of Finafloxacin, Ciprofloxacin, and Levofloxacin in Serum and Urine against TEM- and SHV-Type Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections.The impact of production of extended-spectrum β-lactamases on the 28-day mortality rate of patients with Proteus mirabilis bacteremia in Korea.High diversity of extended-spectrum beta-lactamase-producing bacteria in an urban river sediment habitat.ESBL Production Among E. coli and Klebsiella spp. Causing Urinary Tract Infection: A Hospital Based Study.Prevalence and clonal relationship of ESBL-producing Salmonella strains from humans and poultry in northeastern Algeria.Enzymatic analysis of the effect of naturally occurring Leu138Pro mutation identified in SHV β-lactamase on hydrolysis of penicillin and ampicillin.Seagulls and beaches as reservoirs for multidrug-resistant Escherichia coliExploring the inhibition of CTX-M-9 by beta-lactamase inhibitors and carbapenems.Meningitis caused by Escherichia coli producing TEM-52 extended-spectrum beta-lactamase within an extensive outbreak in a neonatal ward: epidemiological investigation and characterization of the strainBench-to-bedside review: The role of beta-lactamases in antibiotic-resistant Gram-negative infections.Evaluation of a DNA microarray, the check-points ESBL/KPC array, for rapid detection of TEM, SHV, and CTX-M extended-spectrum beta-lactamases and KPC carbapenemases.Possibility of CTX-M-14 Gene Transfer from Shigella sonnei to a Commensal Escherichia coli Strain of the Gastroenteritis Microbiome.Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coliComplicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria.Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance.Mini-review: Epidemiology and zoonotic potential of multiresistant bacteria and Clostridium difficile in livestock and food.Analysis of β-lactamase phenotypes and carriage of selected β-lactamase genes among Escherichia coli strains obtained from Kenyan patients during an 18-year period.Barriers to the effective treatment of sepsis: antimicrobial agents, sepsis definitions, and host-directed therapies.Nationwide high prevalence of CTX-M and an increase of CTX-M-55 in Escherichia coli isolated from patients with community-onset infections in Chinese county hospitalsThe changing epidemiology of resistance.Impact of the use of β-lactam antimicrobials on the emergence of Escherichia coli isolates resistant to cephalosporins under standard pig-rearing conditions.Comparison of ESBL--and AmpC producing Enterobacteriaceae and methicillin-resistant Staphylococcus aureus (MRSA) isolated from migratory and resident population of rooks (Corvus frugilegus) in Austria
P2860
Q24594289-F8C56838-7AA3-4A90-A491-871EC9C63B93Q24612271-D77DF6E7-126A-4159-A7A1-C250B20B7E65Q24617818-37B6286B-3081-4FEB-B903-278B765EA4ABQ26999905-A7C4831A-3197-4674-89BB-E7EFC40FEB82Q27015697-349D8947-FECE-4B9A-A74C-BFB24B5D6043Q27026917-B2E906A6-C6AC-4F13-A02F-2B6B99F7CA03Q28069941-C305B9C8-F475-4119-95CD-04E2C00C7AE0Q28304497-CA96E9C3-0126-46A8-88BD-6B87E946A1A6Q28474307-5EC9D74E-2A68-49B8-B4EB-A9E04516631AQ29617791-BB98E2AB-C8F7-438D-B17A-D5AEE60D3B58Q30276256-FD3C3A19-7D08-4DE2-AA12-08EFB095F4FFQ30385107-4E791891-C449-413E-B25D-4862AE34D4F1Q30415141-E833E50F-22D2-40B5-B885-1EA718F8A221Q30491327-8003ADDC-35F8-4932-A63E-61731B82DEFEQ30986331-D9F7CDF3-2456-46CE-A877-BAAE02EFF3E8Q31079625-FBBE6D8F-93DF-4420-A122-EE9701DED029Q33396218-73CF08C0-8DFC-4994-861B-101D9847DDC6Q33470269-CCA19A2F-71EB-44D0-BEE0-1F06BAB62492Q33601794-E7EB71B4-F183-4116-A9B5-63FE656509A7Q33634460-0EAC9A0C-EFD7-42C3-AA7D-F15528366666Q33635196-01B010EB-99E0-4050-95ED-B60015D421FDQ33668402-C43CE38A-D713-4881-AA88-027B93EDDC13Q33691769-9B97DA5E-432E-407A-9EF2-1746C2AFC3E8Q33811386-80C1BCCF-B3E3-4774-AC79-AEB420B56E11Q33868262-87CDA7CA-F88A-4D20-B0EF-CF083C8A701EQ33893632-718F05D3-9629-40AB-A950-D27436E4F704Q33963674-1BE7BBD4-340C-472E-A607-961E1FDD8AD7Q34026758-F469D385-AC07-48B6-BDE2-C9489D163094Q34045460-0FCE1223-35EF-4196-BDBD-D1676EBE2BFBQ34100513-3C2A6D28-75A4-4AD5-986E-D0FE9C04AEAAQ34108735-A5D8DC89-8082-404C-A05E-EB0B190C2F47Q34140513-7C172693-C82B-40A1-AC68-C329A6614AFDQ34163308-1EB4564F-D020-4996-8EDA-27943CB210CCQ34284603-F2BE49D5-3131-47CD-9C24-C43534E62DB6Q34354019-BF02292E-F2E4-4E02-A7F1-B7B4806C77A7Q34418911-6C3BD3C2-067A-4256-B6EC-94118D02E8B8Q34694361-4DAB1460-9A74-4796-A088-1560C2D78E18Q34997021-64DC5ACE-5CDD-4999-91BC-7F659A89B463Q35075032-714A0B2F-1620-4331-99F2-5CF0DA50D21AQ35082753-E96BB248-9A36-4D19-84F7-04B5A85E419F
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
CTX-M: changing the face of ESBLs in Europe.
@ast
CTX-M: changing the face of ESBLs in Europe.
@en
type
label
CTX-M: changing the face of ESBLs in Europe.
@ast
CTX-M: changing the face of ESBLs in Europe.
@en
prefLabel
CTX-M: changing the face of ESBLs in Europe.
@ast
CTX-M: changing the face of ESBLs in Europe.
@en
P2093
P50
P356
P1476
CTX-M: changing the face of ESBLs in Europe.
@en
P2093
David M Livermore
Francesco Luzzaro
Gian Maria Rossolini
Guillaume Arlet
Juan Ayala
Marek Gniadkowski
Rafael Canton
Teresa M Coque
P304
P356
10.1093/JAC/DKL483
P407
P577
2006-12-06T00:00:00Z